Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLHI) in the transgenic adenocarcinoma of the mouse prostate model

Prostate

Volumn 55, Issue 4, 2003, Pages 308-316

  Schmittgen, Thomas D ^a,c   Zakrajsek, Brian A ^a   Hill, Richard E ^a   Liu, Qian ^a   Reeves, Jerry J ^a   Axford, Paul D ^a   Singer, Michael J ^b   Reed, Michael W ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Nanogen Inc USA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

NAALADase; Prostate cancer; Real time PCR; TRAMP model

Indexed keywords

COMPLEMENTARY RNA; GAMMA GLUTAMYL HYDROLASE; MESSENGER RNA; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN FOLH1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BRAIN; CANCER MODEL; CONTROLLED STUDY; ENZYME ASSAY; KIDNEY; LIVER; LUNG; LYMPH NODE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SEMINAL VESICLE; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; CARBOXYPEPTIDASES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE CARBOXYPEPTIDASE II; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 0038136971     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10241     Document Type: Article

References (19)

1. Wright GL Jr., Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific memebrane antigen in normal, benign,and malignant prostate tissues. Urol Oncol 1995;1:18-28.
2. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-640.
3. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198.
4. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
5. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 2000;38:208-217.
6. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999;39:54-59.
7. Pinto JT, Suffoletto B, Berzin TM, Qiao CH, Lin SL, Tong WP, May F, Mukherjee B, Heston WDW. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-1451.
8. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93:749-753.
9. Pangalos MN, Neefs JM, Somers M, Verhasselt P, Bekkers M, van der Helm L, Fraiponts E, Ashton D, Gordon RD. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J Biol Chem 1999;274:8470-8483.
10. O'Keefe DS, Bacich DJ, Heston WDW. Prostate specific membrane antigen. In: Chung WK, Issacs WB, Simons JW, editors. Prostate cancer: Biology, genetics and the new therapeutics, Totowa, NJ (USA): Human Press; 2001. pp 307-326.
11. Bacich DJ, Pinto JT, Tong WP, Heston WD. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001;12:117-123.
12. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: Prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 2001;61:5857-5860.
13. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol 1996;24:502-504.
14. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
15. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8:230-239.
16. Schmittgen TD, Zakrajsek BA. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000;46:69-81.
17. Tirmenstein MA, Nicholls-Grzemski FA, Schmittgen TD, Zakrajsek BA, Fariss MW. Nitric oxide production by isolated rat hepatocyte suspensions. Toxicol Sci 2000;53:56-62.
18. Kutyavin IV, Afonina IA, Mills AG, Gorn V, Lukhtanov EA, Belousov ES, Singer MJ, Walburger D, Lokhov SG, Gall AA, Dempcy R, Reed MW, Meyer RB, Hedgpeth J. 3′-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 2000;28:655-661.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.